Clinical rigor for small-cap hem/onc

Reading the trial data before the market prices it in.

Stevenson HemOnc Advisors pairs board-certified hematology/oncology judgment with balance-sheet-level financial diligence — for small-cap firms and investors who need to know whether a late-stage readout, and the company behind it, will actually hold up.

Work with us Read the Differential →
Phase IWatching
Phase IICore focus
Phase IIICore focus
Filed / ApprovedPost-mortem
15+
Years in hematology/oncology clinical practice
2×
Former Department Chair & Cancer Committee Chairman
Dx→10-Q
Reads trial protocols and SEC filings with equal fluency
1
Physician-led practice — no committee, no junior analyst layer
The Differential

Recent coverage

All insights →
Aug 2026AML · Small-Cap

Three small-cap AML plays racing toward pivotal readouts

SELLAS, Actinium, and Moleculin all have hematologic-malignancy assets nearing Phase 3 events — but only one of them can fund its way to the finish line without diluting hard.

Clinical signalStrong
Reg. pathModerate
Balance sheetMixed
Jul 2026WM · CLL

What a Breakthrough Therapy designation actually buys you

Investors treat BTD as a stamp of approval. It isn't one — it's a faster meeting schedule. Here's what changes and what doesn't for a confirmatory trial.

Clinical signalStrong
Reg. pathClear
Balance sheetWatch
Jul 2026Diligence Note

Reading an event-driven Phase 3: what "78 of 80" actually tells you

Event-driven survival trials report progress in a way that looks precise and is almost entirely uninformative about the result. A field guide for the non-clinician.

Clinical signalN/A
Reg. pathExplainer
Balance sheetN/A
What we do

Diligence that reads the protocol and the 10-Q

Clinical review

Trial design & endpoint diligence

An assessment of whether a trial's design, endpoints, and statistical plan can actually support the label the company is telling investors to expect.

Data readout

Readout interpretation, same day

Topline data drops fast and dense. A same-day clinical read on what the numbers mean for approval odds and competitive positioning.

Financial overlay

Balance sheet & runway analysis

Positive data doesn't matter if the company can't fund its way to commercialization. Cash runway, dilution risk, and financing structure, plainly explained.

See all services →
Dustin Stevenson, founder of Stevenson HemOnc Advisors
About the firm

One physician. No layers between you and the read.

Stevenson HemOnc Advisors is built around a single perspective: fifteen-plus years of hematology/oncology practice — spanning academic medicine, military medicine, and institutional cancer-center leadership — applied directly to how small-cap trials are designed, read, and financed.

No junior analysts translating your question up a chain. No generalist coverage stretched across therapeutic areas. Just a clinician who has sat on a Cancer Committee, chaired a department, and now reads 10-Qs as closely as protocols.

Full background →

Get the Differential in your inbox.

One clinical read on small-cap hem/onc catalysts, sent when there's something worth saying — not on a schedule.